KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Other Non-Current Assets data on record, last reported at $1.9 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 24.95% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 24.95%, while the annual FY2025 figure was $1.9 million, 24.95% up from the prior year.
  • Other Non-Current Assets reached $1.9 million in Q4 2025 per RIGL's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.0 million in Q3 2023 and bottomed at $403000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $1.9 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 923.97% in 2023, then tumbled 75.49% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $974000.0 in 2021, then plummeted by 34.29% to $640000.0 in 2022, then surged by 377.34% to $3.1 million in 2023, then tumbled by 50.02% to $1.5 million in 2024, then rose by 24.95% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.9 million in Q4 2025, $1.2 million in Q3 2025, and $4.2 million in Q2 2025.